TBC AstraZeneca Pty Ltd
Product name
TBC
Sponsor
Accepted date
Jan-2024
Active ingredients
trastuzumab deruxtecan
Proposed indication
For the treatment of locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Application type
C (new indication)
Publication date
Jan-2024
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.